TY - JOUR
T1 - Therapeutic potential of oncolytic measles virus
T2 - Promises and challenges
AU - Galanis, E.
PY - 2010/11
Y1 - 2010/11
N2 - Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.
AB - Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=77958501444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958501444&partnerID=8YFLogxK
U2 - 10.1038/clpt.2010.211
DO - 10.1038/clpt.2010.211
M3 - Review article
C2 - 20881957
AN - SCOPUS:77958501444
SN - 0009-9236
VL - 88
SP - 620
EP - 625
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 5
ER -